NCT03413722

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors to Everolimus

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 30 (actual)
• Sponsor: University of Kansas Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve cognitive function by having less effect on brain blood flow.

Conditions

• End Stage Renal Disease

Interventions

Type	Name	Description
DRUG	Tacrolimus	The patient's physician will prescribe drug according to standard practice.
DRUG	Everolimus	The patient's physician will prescribe drug according to standard practice.

Timeline

• Start date: 2018-02-01
• Primary completion: 2021-08-01
• Completion: 2022-10-01
• First posted: 2018-01-29
• Last updated: 2024-10-22

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study